QLS‑111 is a novel topical formulation using Qlaris Bio’s ATP-sensitive potassium channel modulator platform. QLS-111 lowers ...
Qlaris Bio is seeing double when it comes to phase 2 wins for its eye drug, hitting the primary endpoints in trials that both spanned primary open angle glaucoma (POAG) and ocular hypertension (OHT).
Qlaris Bio, Inc., a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced positive topline results from two U.S. Phase II clinical trials ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results